International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76

WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 477 International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 76 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in Cumulative List No. 16, 2015 (available in CD-ROM only). Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 76 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la Liste récapitulative No. 16, 2015 (disponible sur CD-ROM seulement). Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 76 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en Cumulative List No. 16, 2015 (disponible sólo en CD-ROM). Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 478 Latin, English, French, Spanish: Recommended INN DCI Recommandée DCI Recomendada Chemical name or description; Molecular formula; Graphic formula Nom chimique ou description; Formule brute; Formule développée Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada acebilustatum acebilustat 4-{[(1S,4S)-5-({4-[4-(1,3-oxazol- 2-yl)phenoxy]phenyl}methyl)- 2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl}benzoic acid acébilustat acide 4-{[(1S,4S)-5-({4-[4-(1,3-oxazol- 2-yl)phénoxy]phényl}méthyl)- 2,5-diazabicyclo[2.2.1]heptan-2-yl]méthyl}benzoïque acebilustat ácido 4-{[(1S,4S)-5-({4-[4-(1,3-oxazol- 2-il)fenoxi]fenil}metil)-2,5-diazabiciclo[2.2.1]heptan- 2-il]metil}benzoico C29H27N3O4 alalevonadifloxacinum alalevonadifloxacin (5S)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro- 5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline- 2-carboxylic acid alalévonadifloxacine acide (5S)-8-[4-(L-alanyloxy)pipéridin-1-yl]-9-fluoro- 5-méthyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline- 2-carboxylique alalevonadifloxacino ácido (5S)-8-[4-(L-alaniloxi)piperidin-1-il]-9-fluoro- 5-metil-1-oxo-6,7-dihidro-1H,5H-pirido[3,2,1-ij]quinolina- 2-carboxílico C22H26FN3O5 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 479 albusomatropinum # albusomatropin human serum albumin (residues 1-585) fusion protein with human somatotropin (growth hormone) (residues 586- 776), produced in yeast cells (Saccharomyces cerevisiae) albusomatropine albumine sérique humaine (résidus 1-585) protéine de fusion avec la somatotropine humaine (hormone de croissance) (résidus 586-776), produit par culture de levure (Saccharomyces cerevisiae) albusomatropina albúmina sérica humana (restos 1-585) proteína de fusión con la somatotropina humana (hormona de crecimiento) (restos 586-776), producida mediante cultivo de levadura (Saccharomyces cerevisiae) Sequence/ Séquence / Secuencia DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 50 KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE 100 CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150 APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 200 ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 250 LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 300 DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA 350 KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400 YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE 450 DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500 EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550 FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGLFPTIP LSRLFDNAML 600 RAHRLHQLAF DTYQEFEEAY IPKEQKYSFL QNPQTSLCFS ESIPTPSNRE 650 ETQQKSNLEL LRISLLLIQS WLEPVQFLRS VFANSLVYGA SDSNVYDLLK 700 DLEEGIQTLM GRLEDGSPRT GQIFKQTYSK FDTNSHNDDA LLKNYGLLYC 750 FRKDMDKVET FLRIVQCRSV EGSCGF 776 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 53-62 75-91 90-101 124-169 168-177 200-246 245-253 265-279 278-289 316-361 360-369 392-438 437-448 461-477 476-487 514-559 558-567 638-750 767-774 asunerceptum # asunercept fusion protein for immune applications (FPIA) comprising the Homo sapiens FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR) superfamily member 6, FAS1, APO-1, CD95) extracellular domain, fused with Homo sapiens immunoglobulin G1 Fc fragment; Homo sapiens FAS precursor fragment 26-172 (1-147) - gamma1 chain H-CH2-CH3 fragment [Homo sapiens IGHG1*03 (hinge 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimer (148- 148':154-154':157-157')-trisdisulfide asunercept protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d’Homo sapiens FAS (récepteur de mort membranaire Fas, TNFRSF6, membre 6 de la superfamille des récepteurs du facteur de nécrose tumorale (TNFR), FAS1, APO-1, CD95), fusionné au fragment Fc de l’immunoglobuline G1 d’Homo sapiens; Homo sapiens FAS fragment 26-172 du précurseur (1- 147)-fragment H-CH2-CH3 de la chaîne gamma1 [Homo sapiens IGHG1*03 (charnière 5-15 (148-158), CH2 (159- 268), CH3 (269-373), CHS (374-375))] (148-375); dimère (148-148':154-154':157-157')-trisdisulfure Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 480 asunercept proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende el dominio extracelular de Homo sapiens FAS (receptor de muerte Fas de membrana, TNFRSF6, miembro 6 de la superfamilia de receptores del factor de necrosis tumoral (TNFR), FAS1, APO-1, CD95), fusionado con el fragmento Fc de la inmunoglobulina G1 de Homo sapiens; FAS de Homo sapiens fragmento 26-172 del precursor (1- 147) -fragmento H-CH2-CH3 de la cadena gamma1 [Homo sapiens IGHG1*03 (bisagra 5-15 (148-158), CH2 (159- 268), CH3 (269-373), CHS (374-375))] (148-375); dímero (148-148':154-154':157-157')-trisdisulfuro Fused chain / chaine fusionnée / cadena fusionadaQVTDINSKGL ELRKTVTTVE TQNLEGLHHD GQFCHKPCPP GERKARDCTV 50 NGDEPDCVPC QEGKEYTDKA HFSSKCRRCR LCDEGHGLEV EINCTRTQNT 100 KCRCKPNFFC NSTVCEHCDP CTKCEHGIIK ECTLTSNTKC KEEGSRSCDK 150 THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE 200 VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK 250 VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSREEMTKNQ VSLTCLVKGF 300 YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV 350 FSCSVMHEAL HNHYTQKSLS LSPGK 375 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intrachain FAS 34-48 38-57 60-76 79-94 82-102 104-118 121-132 124-140 34'-48' 38'-57' 60'-76' 79'-94' 82'-102' 104'-118' 121'-132' 124'-140' IGHG1 (C23-C104) 189-249 295-353 189'-249' 295'-353' Interchain IGHG1 (h5, h 11, h 14) 148-148' 154-154' 157-157' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación FAS: 93, 111, 93', 111': complex mono-, bi-, tri- and tetra-antennary oligosaccharides, partially sialylated, oligosaccharides complexes de structure ramifiée (de 1 à 4 branches), partiellement sialylés, oligosacáridos complejos mono-bi, tri y tetra-antenado, parcialmente sialilados IGHG1 CH2 N84.4: 225, 225': complex mono- and biantennary non-sialylated oligosaccharides, oligosaccharides complexes de structure ramifiée (de 1 à 2 branches) non-sialylés, oligosacáridos complejo mono- and biantenado non-sialilado Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales: H CHS K2 C-terminal lysine clipping, coupure de la lysine C-terminale, supresión de lisina C-terminal: 375, 375' avacopanum avacopan (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro- 6-methylbenzoyl)-N-[4-methyl- 3-(trifluoromethyl)phenyl]piperidine-3-carboxamide avacopan (2R,3S)-2-[4-(cyclopentylamino)phényl]-1-(2-fluoro- 6-méthylbenzoyl)-N-[4-méthyl- 3-(trifluorométhyl)phényl]pipéridine-3-carboxamide avacopán (2R,3S)-2-[4-(ciclopentilamino)fenil]-1-(2-fluoro- 6-metilbenzoil)-N-[4-metil- 3-(trifluorometil)fenil]piperidina-3-carboxamida C33H35F4N3O2 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 481 bazlitoranum bazlitoran all-P-ambo-2'-deoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanylyl- (3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-deoxy- 5-methyl-P-thiocytidylyl-(3'→5')-7-carba-2'-deoxy- P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanylyl- (3'→5')-2'-O-methyluridine bazlitoran tout-P-ambo-2'-déoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl- (3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-déoxy- 5-méthyl-P-thiocytidylyl-(3'→5')-7-carba-2'-déoxy- P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')- P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl- (3'→5')-2'-O-méthyluridine bazlitorán todo-P-ambo-2'-desoxi-P-tiocitidilil-(3'→5')- P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')- P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')- P-tiotimidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O- metil-P-tiouridilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil- (3'→5')-7-carba-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil- (3'→5')-P-tiotimidilil-(3'→5')- 2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')- 2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')- 2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metiluridina C179H233N52O101P17S17 (3'-5')d(P-thio)(C-T-A-T-C-T-rGm-rUm-m5C-c7G- T-T-C-T-C-T-rGm-rUm) Legend: rGm = 2'-O-méthylguanosine rUm = 2'-O-méthyluridine m5C = 2'-deoxy-5-methylcytidine c7G = 2'-deoxy-7-carbaguanosine (C replaces N) bevacizumabum beta # bevacizumab beta immunoglobulin G1-kappa, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody; Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 482 gamma1 heavy chain (1-453) [humanized VH (Homo sapiens IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*03 (CH1 R120>K (220) (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (232-232":235-235")-bisdisulfide bévacizumab bêta immunoglobuline G1-kappa, anti-[Homo sapiens VEGFA (facteur de croissance A de l’endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-453) [VH humanisé (Homo sapiens IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*03 (CH1 R120>K (220) (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé (Homo sapiens IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (232-232":235-235")-bisdisulfure bevacizumab beta inmunoglobulina G1-kappa, anti-[Homo sapiens VEGFA (factor de crecimiento A endotelial vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-453) [VH humanizado (Homo sapiens IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -Homo sapiens IGHG1*03 (CH1 R120>K (220) (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1’-214’) [V-KAPPA humanizado (Homo sapiens IGKV1-16*01 (88.40%) - IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 483 blontuvetmabum # blontuvetmab immunoglobulin G2_V-kappa-C-lambda, anti-[Homo sapiens MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], caninized monoclonal antibody; gamma2 heavy chain chimeric (1-448) [Mus musculus VH (Mus musculus IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -Canis lupus familiaris IGHG2*02 (CH1 T26>Q (131) (114-211), hinge (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfide with V-kappa-C-lambda light chain chimeric (1'-219') [Mus musculus V-KAPPA (Mus musculus IGKV8-30*01 - IGKJ5*01) [12.3.9] (1'-112') -Canis lupus familiaris IGL1CS1*01 V45.3>I (162) (114'-219')]; dimer (225- 225'':228-228'')-bisdisulfide blontuvetmab immunoglobuline G2_V-kappa-C-lambda, anti-[Homo sapiens MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal caninisé; chaîne lourde gamma2 chimérique (1-448) [Mus musculus VH (Mus musculus IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -Canis lupus familiaris IGHG2*02 (CH1 T26>Q (131) (114-211), charnière (212-229), CH2 (230- 339), CH3 (340-446), CHS (447-448)) (114-448)], (128- 218')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-219') [Mus musculus V-KAPPA (Mus musculus IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') - Canis lupus familiaris IGL1CS1*01 V45.3>I (162) (114'- 219')]; dimère (225-225'':228-228'')-bisdisulfure blontuvetmab inmunoglobulina G2_V-kappa-C-lambda, anti-[Homo sapiens MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal caninizado; cadena pesada gamma2 quimérica (1-448) [Mus musculus VH (Mus musculus IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -Canis lupus familiaris IGHG2*02 (CH1 T26>Q (131) (114-211), bisagra (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')- disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-219') [Mus musculus V-KAPPA (Mus musculus IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') - Canis lupus familiaris IGL1CS1*01 V45.3>I (162) (114'- 219')]; dímero (225-225'':228-228'')-bisdisulfuro Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 484 brimapitidum brimapitide D-α-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl- D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl- D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl- D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl- D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl- D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide brimapitide D-α-aspartyl-D-glutaminyl-D-séryl-D-arginyl-D-prolyl-D-valyl- D-glutaminyl-D-prolyl-D-phénylalanyl-D-leucyl- D-asparaginyl-D-leucyl-D-thréonyl-D-thréonyl- D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl- D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl- D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide brimapitida D-α-aspartil-D-glutaminil-D-seril-D-arginil-D-prolil- D-valil-D-glutaminil-D-prolil-D-fenilalanil-D-leucil- D-asparaginil-D-leucil-D-treonil-D-treonil-D-prolil- D-arginil-D-lisil-D-prolil-D-arginil-D-prolil-D-prolil- D-arginil-D-arginil-D-arginil-D-glutaminil-D-arginil- D-arginil-D-lisil-D-lisil-D-arginilglicinamida C164H286N66O40 D-Aminoacids sequence / Séquence des D-aminoacides / Secuencia de D-aminoácidos DQSRPVQPFL NLTTPRKPRP PRRRQRRKKR G 31 Modified residue / Résidu modifié / Resto modificado G = glycinamide WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 485 cabiralizumabum # cabiralizumab immunoglobulin G4-kappa, anti-[Homo sapiens CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody; gamma4 heavy chain (1-449) [humanized VH (Homo sapiens IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), hinge S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfide with kappa light chain (1’-218’) [humanized V-KAPPA (Homo sapiens IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - Homo sapiens IGKC*01, Km3 (112'-218')]; dimer (228- 228":231-231")-bisdisulfide cabiralizumab immunoglobuline G4-kappa, anti-[Homo sapiens CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-449) [VH humanisé (Homo sapiens IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), charnière S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfure avec la chaîne légère kappa (1’-218’) [V-KAPPA humanisé (Homo sapiens IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'- 111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimère (228-228":231-231")-bisdisulfure cabiralizumab inmunoglobulina G4-kappa, anti-[Homo sapiens CSF1R (receptor del factor 1 de estimulación de colonias, CSF- 1R, CSF-1-R, receptor del factor 1 de estimulación de colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-449) [VH humanizado (Homo sapiens IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), bisagra S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfuro con la cadena ligera kappa (1’-218’) [V-KAPPA humanizado (Homo sapiens IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dímero (228-228":231-231")-bisdisulfuro Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 486 Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD 50 INPYNGGTTF NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARES 100 PYFSNLYVMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200 KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350 YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK 449 Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCKASQSVD YDGDNYMNWY QQKPGQAPRL 50 LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS 100 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200 THQGLSSPVT KSFNRGEC 218 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 149-205 263-323 369-427 22''-96'' 149''-205'' 263''-323'' 369''-427'' Intra-L (C23-C104) 23'-92' 138'-198' 23'''-92''' 138'''-198''' Inter-H-L (CH1 10-CL 126) 136-218' 136''-218''' Inter-H-H (h 8, h 11) 228-228'' 231-231'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 299, 299'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados carotuximabum # carotuximab immunoglobulin G1-kappa, anti-[Homo sapiens ENG (endoglin, Osler-Rendu-Weber syndrome 1, ORW1, ORW, HHT1, CD105)], chimeric monoclonal antibody; gamma1 heavy chain (1-448) [Mus musculus VH (IGHV6- 6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfide with kappa light chain (1'-213') [chimeric V-KAPPA (Mus musculus IGKV4-72*01 -Homo sapiens IGKJ5*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')]; dimer (227-227'':230-230'')- bisdisulfide carotuximab immunoglobuline G1-kappa, anti-[Homo sapiens ENG (endogline, syndrome 1 d’Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [Mus musculus VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447- 448)) (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA chimérique (Mus musculus IGKV4-72*01 - Homo sapiens IGKJ5*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')]; dimère (227-227'':230-230'')- bisdisulfure carotuximab inmunoglobulina G1-kappa, anti-[Homo sapiens ENG (endoglina, síndrome 1 de Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticuerpo monoclonal quimérico; WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 487 cadena pesada gamma1 (1-448) [Mus musculus VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217- 231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA quimérico (Mus musculus IGKV4- 72*01 -Homo sapiens IGKJ5*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')]; dímero (227-227'':230- 230'')-bisdisulfuro cefiderocolum cefiderocol (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2- carboxypropan-2-yl)oxy]imino}acetamido]-3-({1-[2-(2- chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium- 1-yl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene- 2-carboxylate céfidérocol (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2- carboxypropan-2-yl)oxy]imino}acétamido]-3-({1-[2-(2- chloro-3,4-dihydroxybenzamido)éthyl]pyrrolidin-1-ium- 1-yl}méthyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène- 2-carboxylate cefiderocol (6R,7R)-7-[(2Z)-2-(2-amino-1,3-tiazol-4-il)-2-{[(2- carboxipropan-2-il)oxi]imino}acetamido]-3-({1-[2-(2-cloro- 3,4-dihidroxibenzamido)etil]pirrolidin-1-ium-1-il}metil)- 8-oxo-5-tia-1-azabiciclo[4.2.0]oct-2-ene-2-carboxilato Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 488 C30H34ClN7O10S2 cemdisiranum cemdisiran duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D- galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2- deoxy-β-D-galactopyranosyl)oxy]pentanamido} propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14- oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin- 2-yl]methyl hydrogen all-P-ambo-2'-O-methyl-P- thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'- deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methylcytidylyl- (3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O- methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')- 2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl- (3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'- fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy- 2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O- methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'- O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')- 2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'- O-methyl-3'-adenylate and all-P-ambo-thymidylyl-(5'→3')- thymidylyl-(5'→3')-2'-O-methyl-P-thiouridylyl-(5'→3')-2'-O- methyl-P-thiouridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'- O-methyluridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')- 2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-O-methyluridylyl- (5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O- methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')- 2'-O-methyladenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')- 2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl- (5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'- fluoroadenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O- methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')- 2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiouridylyl- (5'→3')-2'-deoxy-2'-fluoro-P-thioadenylyl-(5'→3')-2'-O- methyluridine cemdisiran duplex de l'hydrogéno-tout-P-ambo-2'-O-méthyl- P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')- 2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-méthylcytidylyl- (3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O- méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')- 2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl- (3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy- 2'-fluorouridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')- 2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyluridylyl- (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy- 2'-fluoroadénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')- 2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O-méthyladénylyl- (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyl-3'- adénylate de WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 489 [(2S,4R)-1-{1-[(2-acétamido-2-déoxy-β-D- galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido- 2-déoxy-β-D-galactopyranosyl)oxy]pentanamido} propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14- oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin- 2-yl]méthyle et de tout-P-ambo-thymidylyl-(5'→3')- thymidylyl-(5'→3')-2'-O-méthyl-P-thiouridylyl-(5'→3')-2'-O- méthyl-P-thiouridylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'- O-méthyluridylyl-(5'→3')-2'-O-méthylcytidylyl-(5'→3')- 2'-déoxy-2'-fluoroguanylyl-(5'→3')-2'-O-méthyluridylyl- (5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O- méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')- 2'-O-méthyladénylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')- 2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl- (5'→3')-2'-O-méthyladénylyl-(5'→3')-2'-déoxy- 2'-fluoroadénylyl-(5'→3')-2'-O-méthyladénylyl-(5'→3')-2'-O- méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')- 2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoro-P-thiouridylyl- (5'→3')-2'-déoxy-2'-fluoro-P-thioadénylyl-(5'→3')-2'-O- méthyluridine cemdisirán dúplex del hidrógeno-todo-P-ambo-2'-O-metil- P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')- 2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')- 2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-O-metiladenilil-(3'→5')- 2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')- 2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil- (3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiluridilil- (3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiluridilil- (3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil- (3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil- (3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')- 2'-O-metil-3'-adenilato de [(2S,4R)-1-{1-[(2-acetamido- 2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2- acetamido-2-desoxi-β-D- galactopiranosil)oxi]pentanamido}propil)amino]- 3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17- triazanonacosan-29-oil}-4-hidroxipirrolidín-2-yl]metil y de todo-P-ambo-timidilil-(5'→3')-timidilil-(5'→3')- 2'-O-metil-P-tiouridilil-(5'→3')-2'-O-metil-P-tiouridilil-(5'→3')- 2'-O-metiluridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O- metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-O- metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O- metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O- metiladenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O- metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O- metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O- metiladenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi- 2'-fluoro-P-tiouridilil-(5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil- (5'→3')-2'-O-metiluridina Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 490 C542H711F17N169O330P45S6 clivatuzumabum tetraxetanum # clivatuzumab tetraxetan immunoglobulin G1-kappa, anti-[Homo sapiens MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - Homo sapiens IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (Homo sapiens IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; (228-228":231-231")- bisdisulfide dimer; tetraxetan (DOTA) conjugate (on an average of 4 to 7 lysyl, linked to the chelator by their N6) clivatuzumab tétraxétan immunoglobuline G1-kappa, anti-[Homo sapiens MUC1 (mucine 1, mucine épithéliale polymorphique, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan; chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - Homo sapiens IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (Homo sapiens IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; dimère (228-228":231-231")- bisdisulfure; conjugué au tétraxétan (DOTA) (avec une moyenne de 4 à 7 lysyl liés au chélateur par leur N6) clivatuzumab tetraxetán inmunoglobulina G1-kappa, anti-[Homo sapiens MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado con tetraxetán; WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 491 cadena pesada gamma1 (1-449) [VH humanizado (Homo sapiens IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - Homo sapiens IGHG1*03, G1m3 (CH1 (120-217), (bisagra 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (Homo sapiens IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; dímero (228- 228":231-231")-bisdisulfuro; conjugado con tetraxetán (DOTA) (con una media de 4 a 7 restos lisil unidos al quelante por sus respectivos N6) N N N N CO2H CO2HHO2C NH H O N H O C 4 to 7 lysyl (K) 4 à 7 lysyl (K) 4 a 7 lisil (K) N6-(tetraxetan)-L-lysyl Heavy chain / Chaîne lourde / Cadena pesada QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY 50 INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSRLRSDD TAVYYCARGF 100 GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200 ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449 Light chain / Chaîne légère / Cadena ligera DIQLTQSPSS LSASVGDRVT MTCSASSSVS SSYLYWYQQK PGKAPKLWIY 50 STSNLASGVP ARFSGSGSGT DFTLTISSLQ PEDSASYFCH QWNRYPYTFG 100 GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150 VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200 GLSSPVTKSF NRGEC 215 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 146-202 263-323 369-427 22''-96'' 146''-202'' 263''-323'' 369''-427'' Intra-L (C23-C104) 23'-89' 135'-195' 23'''-89''' 135'''-195''' Inter-H-L (h 5-CL 126) 222-215' 222''-215''' Inter-H-H (h 11, h 14) 228-228'' 231-231'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 299, 299'' Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados Modified residues / Résidus modifies / Restos modificados crotedumabum # crotedumab immunoglobulin G4-kappa, anti-[Homo sapiens GCGR (glucagon receptor)], Homo sapiens monoclonal antibody; gamma4 heavy chain (1-455) [Homo sapiens VH (IGHV3- 7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) - IGHG4*01 (CH1 (129-226), hinge S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129- 455)], (142-214')-disulfide with kappa light chain (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-17*01 (95.80%) - IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (234-234":237-237")-bisdisulfide Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 492 crotédumab immunoglobuline G4-kappa, anti-[Homo sapiens GCGR (récepteur du glucagon)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-455) [Homo sapiens VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1- 128) -IGHG4*01 (CH1 (129-226), charnière S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454- 455)) (129-455)], (142-214')-disulfure avec la chaîne légère kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'- 214')]; dimère (234-234":237-237")-bisdisulfure crotedumab inmunoglobulina G4-kappa, anti-[Homo sapiens GCGR (receptor de glucagón)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma4 (1-455) [Homo sapiens VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1- 128) -IGHG4*01 (CH1 (129-226), bisagra S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454- 455)) (129-455)], (142-214')-disulfuro con la cadena ligera kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'- 214')]; dímero (234-234":237-237")-bisdisulfuro dapansutrilum dapansutrile 3-(methanesulfonyl)propanenitrile dapansutrile 3-(méthanesulfonyl)propanenitrile dapansutrilo 3-(metanosulfonil)propanonitrilo WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 493 C4H7NO2S deudextromethorphanum deudextromethorphan 3-[(2H3)methoxy]-17-[(2H3)methyl]-ent-morphinan deudextromethorphane 3-[(2H3)méthoxy]-17-[(2H3)méthyl]-ent-morphinane deudextrometorfano 3-[(2H3)metoxi]-17-[(2H3)metil]-ent-morfinano C18H192H6NO dociparstatum natricum dociparstat sodium sodium salt of 2,3-di-O-desulfoheparin, the starting material is an unfractionated heparin from porcine intestinal mucosa, the relative average molecular mass is approximately 12,000 daltons with about 40% ranging between 8,000 and 16,000 daltons, the degree of sulfation is about 2.0 per disaccharidic unit dociparstat sodique sel de sodium de la 2,3-di-O-désulfohéparine, obtenu à partir d’héparine non-fractionnée de la muqueuse intestinale porcine; sa masse moléculaire relative dont environ 40% est comprise entre 8.000 et 16.000 daltons, est voisine de 12.000 daltons; son degré de sulfatation est d’environ 2,0 par unité disaccharide dociparstat sodico sal de sodio de la 2,3-di-O-desulfoheparina, obtenida a partir de la heparina no fraccionad de la mucosa intestinal porcina; la masa molecular relativa media es aproximadamente de 12000 daltons con el 40% comprendido entre 8000 y 16000 daltons; el grado de sulfatación es de 2,0 por unidad de disacárido. Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 494 dolcanatidum dolcanatide 1D,16D-[3-L-glutamic acid]human uroguanylin: S4,S12:S7,S15-dicyclo(D-asparaginyl-L-α-aspartyl- L-α-glutamyl-L-cysteinyl-L-α-glut-amyl-L-leucyl-L-cysteinyl- L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl- L-threonylglycyl-L-cysteinyl-D-leucine) dolcanatide 1D,16D-[3-acide L-glutamique]uroguanyline humaine: S4,S12:S7,S15-dicyclo(D-asparaginyl-L-α-aspartyl -L-α-glutamyl-L-cystéinyl-L-α-glut-amyl-L-leucyl-L-cystéinyl- L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cystéinyl- L-thréonylglycyl-L-cystéinyl-D-leucine) dolcanatida 1D,16D-[3-L-ácido glutámico]uroguanilina humana: S4,S12:S7,S15-diciclo(D-asparaginil-L-α-aspartil-L-α-glutamil- L-cisteinil-L-α-glut-amil-L-leucil-L-cisteinil-L-valil- L-asparaginil-L-valil-L-alanil-L-cisteinil-L-treonilglicil- L-cisteinil-D-leucina) C65H104N18O26S4 domagrozumabum # domagrozumab immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (growth differentiation factor 8, GDF8, myostatin,GDF-8)], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (Homo sapiens IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), hinge (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1’- 214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")- bisdisulfide domagrozumab immunoglobuline G1-kappa, anti-[Homo sapiens MSTN (facteur de croissance et de différenciation 8, GDF8, myostatine, GDF-8)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiens IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')- disulfure avec la chaîne légère (1’-214’) [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (225- 225":228-228")-bisdisulfure WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 495 domagrozumab inmunoglobulina G1-kappa, anti-[Homo sapiens MSTN (factor de crecimiento y de diferenciación 8, GDF8, miostatina, GDF-8)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizado (Homo sapiens IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), bisagra (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445- 446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1’-214’) [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (225-225":228- 228")-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVST 50 ISSGGSYTSY PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD 100 YAMNYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200 VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGAPSVF LFPPKPKDTL 250 MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50 ASYRYTGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSTPWTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 143-199 260-320 366-424 22''-96'' 143''-199'' 260''-320'' 366''-424'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (h 5-CL 126) 219-214' 219''-214''' Inter-H-H (h 11, h 14) 225-225'' 228-228'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 296, 296'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales C-terminal trimming of the C-terminal lysine (K) H CHS K2: 446, 446'' edasalonexentum edasalonexent N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19- hexaenamido]ethyl}-2-hydroxybenzamide édasalonexent N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19- hexaénamido]éthyl}-2-hydroxybenzamide edasalonexento N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19- hexaenamido]etil}-2-hidroxibenzamida C28H39N3O2 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 496 edonerpicum edonerpic 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol édonerpic 1-{3-[2-(1-benzothiophén-5-yl)éthoxy]propyl}azétidin-3-ol edonerpico 1-{3-[2-(1-benzotiofen-5-il)etoxi]propil}azetidin-3-ol C16H21NO2S enoblituzumabum # enoblituzumab immunoglobulin G1-kappa, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7RP-2)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (Homo sapiens IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -Homo sapiens IGHG1*03 (CH1 (123- 220), hinge (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (231-231":234-234")-bisdisulfide énoblituzumab immunoglobuline G1-kappa, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7RP-2)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (Homo sapiens IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -Homo sapiens IGHG1*03 (CH1 (123- 220), charnière (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé (Homo sapiens IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-bisdisulfure enoblituzumab inmunoglobulina G1-kappa, anti-[Homo sapiens CD276 (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-452) [VH humanizado (Homo sapiens IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -Homo sapiens IGHG1*03 (CH1 (123- 220), bisagra (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1’-214’) [V-KAPPA humanizado (Homo sapiens IGKV1D-13*01 (85.10%) - IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 497 Heavy chain / Chaîne lourde / Cadena pesadaQVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLELVSS 50 ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARNM 100 YTHFDSWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447 Light chain / Chaîne légère / Cadena ligera DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG SNSVSWYQQL PGTAPKLLIY 50 DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYYCQ SRDTYGYYWV 100 FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150 AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200 HEGSTVEKTV APTECS 216 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L (C23-C104) 22'-89' 138'-197' 22'''-89''' 138'''-197''' Inter-H-L (h 5-CL 126) 220-215' 220''-215''' Inter-H-H (h 11, h 14) 226-226' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 297, 297'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados epacadostatum epacadostat (Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy- 4-{[2-(sulfamoylamino)ethyl]amino}-1,2,5-oxadiazole- 3-carboximidamide épacadostat (Z)-N-(3-bromo-4-fluorophényl)-N'-hydroxy- 4-{[2-(sulfamoylamino)éthyl]amino}-1,2,5-oxadiazole- 3-carboximidamide epacadostat (Z)-N-(3-bromo-4-fluorofenil)-N'-hidroxi- 4-{[2-(sulfamoilamino)etil]amino}-1,2,5-oxadiazol- 3-carboximidamida C11H13BrFN7O4S esaxerenonum esaxerenone (5P)-1-(2-hydroxyethyl)-N-[4-(methanesulfonyl)phenyl]- 4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole- 3-carboxamide ésaxérénone (5P)-1-(2-hydroxyéthyl)-N-[4-(méthanesulfonyl)phényl]- 4-méthyl-5-[2-(trifluorométhyl)phényl]-1H-pyrrole- 3-carboxamide esaxerenona (5P)-1-(2-hidroxietil)-N-[4-(metanosulfonil)fenil]-4-metil- 5-[2-(trifluorometil)fenil]-1H-pirrol-3-carboxamida Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 498 C22H21F3N2O4S fexapotidum fexapotide L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl- L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl- L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl- L-leucine fexapotide L-isoleucyl-L-α-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl- L-leucyl-L-séryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl- L-α-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cystéinyl- L-leucine fexapotida L-isoleucil-L-α-aspartil-L-glutaminil-L-glutaminil-L-valil- L-leucil-L-seril-L-arginil-L-isoleucil-L-lisil-L-leucil-L-α-glutamil- L-isoleucil-L-lisil-L-arginil-L-cisteinil-L-leucina C90H163N27O25S flortaucipirum (18F) flortaucipir (18F) 7-[6-(18F)fluoropyridin-3-yl]-5H-pyrido[4,3-b]indole flortaucipir (18F) 7-[6-(18F)fluoropyridin-3-yl]-5H-pyrido[4,3-b]indole flortaucipir (18F) 7-[6-(18F)fluoropiridin-3-il]-5H-pirido[4,3-b]indol C16H1018FN3 fonadelparum fonadelpar {[5-methyl-3-(2-{4-(propan-2-yl)- 2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)- 1,2-benzoxazol-6-yl]oxy}acetic acid WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 499 fonadelpar acide {[5-méthyl-3-(2-{4-(propan-2-yl)- 2-[4-(trifluorométhyl)phényl]-1,3-thiazol-5-yl}éthyl)- 1,2-benzoxazol-6-yl]oxy}acétique fonadelpar ácido {[5-metil-3-(2-{4-(propan-2-il)- 2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}etil)-1,2-benzoxazol- 6-il]oxi}acético C25H23F3N2O4S galcanezumabum # galcanezumab immunoglobulin G4-kappa, anti-[Homo sapiens CALCA (calcitonin-related polypeptide alpha, calcitonin 1, CALC1) and Homo sapiens CALCB (calcitonin-related polypeptide beta, calcitonin 2, CALC2)], humanized monoclonal antibody; gamma4 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), hinge S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230- 339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133- 214')-disulfide with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (87.40%) - IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide galcanézumab immunoglobuline G4-kappa, anti-[Homo sapiens CALCA (polypeptide alpha apparenté à la calcitonine, calcitonine 1, CALC1) et Homo sapiens CALCB (polypeptide beta apparenté à la calcitonine, calcitonine 2, CALC2)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-445) [VH humanisé (Homo sapiens IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), charnière S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfure avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228") bisdisulfure Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 500 galcanezumab inmunoglobulina G4-kappa, anti-[Homo sapiens CALCA (polipéptido alfa relacionado con la calcitonina, calcitonina 1, CALC1) y Homo sapiens CALCB (polipéptido beta relacionado con la calcitonina, calcitonina 2, CALC2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-445) [VH humanizado (Homo sapiens IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), bisagra S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfuro con la cadena ligera kappa (1’-214’) [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")- bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGSSVKV SCKASGYTFG NYWMQWVRQA PGQGLEWMGA 50 IYEGTGKTVY IQKFADRVTI TADKSTSTAY MELSSLRSED TAVYYCARLS 100 DYVSGFGYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200 TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL 250 MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350 PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400 GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG 445 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRASKDIS KYLNWYQQKP GKAPKLLIYY 50 TSGYHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GDALPPTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 146-202 260-320 366-424 22''-96'' 146''-202'' 260''-320'' 366''-424'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 133-214' 133''-214''' Inter-H-H (h 8, h 11) 225-225'' 228-228'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 296, 296'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados galidesivirum galidesivir (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)- 5-(hydroxymethyl)pyrrolidine-3,4-diol galidésivir (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)- 5-(hydroxyméthyl)pyrrolidine-3,4-diol galidesivir (2S,3S,4R,5R)-2-(4-amino-5H-pirrolo[3,2-d]pirimidin-7-il)-5- (hidroximetil)pirrolidina-3,4-diol C11H15N5O3 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 501 givosiranum givosiran duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D- galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido- 2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl) amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa- 6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2- yl]methyl hydrogen all-P-ambo-2'-O-methyl-P-thiocytidylyl- (3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O- methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O- methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'- deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methyladenylyl- (3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-O- methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'- O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')- 2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl- (3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl- (3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyluridylyl- (3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyl- 3'-adenylate and all-P-ambo-2'-O-methyl-P-thiouridylyl- (5'→3')-2'-O-methyl-P-thioguanylyl-(5'→3')-2'-O- methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')- 2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl- (5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy- 2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')- 2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl- (5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O- methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')- 2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl- (5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy- 2'-fluorouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')- 2'-deoxy-2'-fluoroguanylyl-(5'→3')-2'-deoxy-2'-fluoro- P-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thioadenylyl- (5'→3')-2'-O-methyluridine givosiran duplex de l'hydrogéno-tout-P-ambo-2'-O-méthyl- P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')- 2'-O-méthylguanylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')- 2'-O-méthyladénylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')- 2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O-méthyladénylyl- (3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')- 2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl- (3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'- fluorocytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O- méthyl-3'-adénylate de [(2S,4R)-1-{1-[(2-acétamido-2- déoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2- acétamido-2-déoxy-β-D-galactopyranosyl)oxy] pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18- trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}- 4-hydroxypyrrolidin-2-yl]méthyle et Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 502 du tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(5'→3')-2'-O- méthyl-P-thioguanylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')- 2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidylyl- (5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O- méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'- O-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')- 2'-O-méthylcytidylyl-(5'→3')-2'-déoxy- 2'-fluoroadénylyl-(5'→3')-2'-O-méthylcytidylyl-(5'→3')- 2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl- (5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O- méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')- 2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroguanylyl- (5'→3')-2'-déoxy-2'-fluoro-P-thioadénylyl-(5'→3')-2'-déoxy- 2'-fluoro-P-thioadénylyl-(5'→3')-2'-O-méthyluridine givosirán dúplex del hidrógeno-todo-P-ambo-2'-O-metil-P-tiocitidilil- (3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metilguanilil- (3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')- 2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')- 2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')- 2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')- 2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'- O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O- metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O- metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O- metiluridilil-(3'→5')-2'-O-metil-3'-adenilato de [(2S,4R)-1-{1- [(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16- bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D- galactopiranosil)oxi]pentanamido}propil)amino]- 3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17- triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo y del todo-P-ambo-2'-O-metil-P-tiouridilil-(5'→3')-2'-O-metil- P-tioguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi- 2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi- 2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi- 2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi- 2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi- 2'-fluorouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi- 2'-fluoroguanilil-(5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil- (5'→3')-2'-desoxi-2'-fluoro-P-tioadenilil-(5'→3')-2'-O- metiluridina C524H694F16N173O316P43S6 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 503 glecaprevirum glecaprevir (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)- 2-(difluoromethyl)-1-[(1-methylcyclopropane- 1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo- 2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12- methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclonon adecino[11,12-b]quinoxaline-10-carboxamide glécaprévir (3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-{(1R,2R)- 2-(difluorométhyl)-1-[(1-méthylcyclopropane- 1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo- 2,3,3a,5,6,7,8,11,12,20,23,24a-dodécahydro-1H,10H-9,12- méthanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclonon adécino[11,12-b]quinoxaline-10-carboxamide glecaprevir (3aR,7S,10S,12R,21E,24aR)-7-tert-butil-N-{(1R,2R)- 2-(difluorometil)-1-[(1-metilciclopropano- 1-sulfonil)carbamoil]ciclopropil}-20,20-difluoro-5,8-dioxo- 2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahidro-1H,10H-9,12- metanociclopenta[18,19][1,10,17,3,6]trioxadiazaciclononad ecino[11,12-b]quinoxalina-10-carboxamida C38H46F4N6O9S glesatinibum glesatinib N-[(3-fluoro-4-{[2-(5-{[(2- methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2- b]pyridin-7-yl]oxy}phenyl)carbamothioyl]- 2-(4-fluorophenyl)acetamide glésatinib N-[(3-fluoro-4-{[2-(5-{[(2- méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2- b]pyridin-7-yl]oxy}phényl)carbamothioyl]- 2-(4-fluorophényl)acétamide glesatinib N-[(3-fluoro-4-{[2-(5-{[(2-metoxietil)amino]metil}piridin- 2-il)tieno[3,2-b]piridin-7-il]oxi}fenil)carbamotioil]- 2-(4-fluorofenil)acetamida Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 504 C31H27F2N5O3S2 S H N HNO F F O N S N NH O CH3 inclisiranum inclisiran duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D- galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido- 2-deoxy-β-D-galactopyranosyl)oxy]pentanamido} propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14- oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin- 2-yl]methyl hydrogen all-P-ambo-2'-O-methyl-P- thiocytidylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O- methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O- methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'- deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')- 2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methyluridylyl- (3'→5')-thymidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O- methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O- methylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O- methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O- methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O- methyl-3'-uridylate and all-P-ambo-2'-O-methyl- P-thioadenylyl-(5'→3')-2'-O-methyl-P-thioadenylyl-(5'→3')- 2'-O-methylguanylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')- 2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl- (5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy- 2'-fluoroguanylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')- 2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylcytidylyl- (5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O- methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')- 2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl- (5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy- 2'-fluoroadenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl- (5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyl- P-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiocytidylyl- (5'→3')-2'-O-methyladenosine inclisiran duplex de l'hydrogéno-tout-P-ambo-2'-O-méthyl- P-thiocytidylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')- 2'-O-méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')- 2'-O-méthyladénylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')- 2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthyluridylyl- (3'→5')-2'-déoxy-2'-fluoroguanylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-thymidylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O- méthylguanylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O- méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O- méthylguanylyl-(3'→5')-2'-O-méthyl-3'-uridylate de WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 505 [(2S,4R)-1-{1-[(2-acétamido-2-déoxy- β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2- acétamido-2-déoxy-β-D-galactopyranosyl)oxy] pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18- trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4- hydroxypyrrolidin-2-yl]méthyle et du tout-P-ambo-2'-O- méthyl-P-thioadénylyl-(5'→3')-2'-O-méthyl-P-thioadénylyl- (5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-O-méthyladénylyl- (5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'- fluorocytidylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy- 2'-fluoroguanylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'- déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylcytidylyl- (5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O- méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')- 2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl- (5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'- fluoroadénylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')- 2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthyl-P- thioadénylyl-(5'→3')-2'-déoxy-2'-fluoro-P-thiocytidylyl- (5'→3')-2'-O-méthyladénosine inclisirán dúplex del hidrógeno-todo-P-ambo-2'-O-metil-P-tiocitidilil- (3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metiladenilil- (3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')- 2'-O-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')- 2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')- 2'-O-metiluridilil-(3'→5')-timidilil-(3'→5')-2'-O-metiluridilil- (3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')- 2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O- metiluridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O- metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metil- 3'-uridilato de [(2S,4R)-1-{1-[(2-acetamido-2-desoxi-β-D- galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2- desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]- 3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17- triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo y del todo-P-ambo-2'-O-metil-P-tioadenilil-(5'→3')-2'-O-metil- P-tioadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O- metiladenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi- 2'-fluorocitidilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi- 2'-fluoroguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi- 2'-fluorocitidilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi- 2'-fluoroadenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')- 2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metil-P-tioadenilil- (5'→3')-2'-desoxi-2'-fluoro-P-tiocitidilil-(5'→3')-2'-O- metiladenosina C529H707F12N176O316P43S6 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 506 intepirdinum intepirdine 3-(benzenesulfonyl)-8-(piperazin-1-yl)quinolone intépirdine 3-(benzènesulfonyl)-8-(pipérazin-1-yl)quinolone intepirdina 3-(bencenosulfonil)-8-(piperazin-1-il)quinolina C19H19N3O2S ivosidenibum ivosidenib (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3- difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin- 2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine- 2-carboxamide ivosidénib (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3- difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin- 2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine- 2-carboxamide ivosidenib (2S)-N-{(1S)-1-(2-clorofenil)-2-[(3,3- difluorociclobutil)amino]-2-oxoetil}-1-(4-cianopiridin-2-il)- N-(5-fluoropiridin-3-il)-5-oxopirrolidina-2-carboxamida C28H22ClF3N6O3 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 507 lanadelumabum # lanadelumab immunoglobulin G1-kappa, anti-[Homo sapiens KLKB1 (kallikrein B 1, plasma prekallikrein (zymogen), kininogenin, Fletcher factor) proteolytically cleaved by F12 (factor FXII), active plasma kallikrein (EC 3.4.21.34)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV3- 23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) - IGHG1*03, G1m3 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451))(123-451)], (225-213')-disulfide with kappa light chain (1'-213') [Homo sapiens V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (231- 231'':234-234'')-bisdisulfide lanadélumab immunoglobuline G1-kappa, anti-[Homo sapiens KLKB1 (kallikréine B 1, prékallikréine plasmatique (zymogène), kininogénine, facteur de Fletcher) clivé protéolytiquement par F12 (facteur FXII), kallikréine plasmatique active (EC 3.4.21.34)], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-451) [Homo sapiens VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1- 122) -IGHG1*03, G1m3 (CH1 (123-220), charnière (221- 235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfure avec la chaîne légère kappa (1'-213') [Homo sapiens V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'- 213')]; dimère (231-231'':234-234'')-bisdisulfure lanadelumab inmunoglobulina G1-kappa, anti-[Homo sapiens KLKB1 (kalikreína B 1, prekalikreína plasmática (zimógeno), kininogenina, factor de Fletcher) dividida proteolíticamente por F12 (factor FXII), kalikreína plasmática activa (EC 3.4.21.34)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-451) [Homo sapiens VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1- 122) -IGHG1*03, G1m3 (CH1 (123-220), bisagra (221- 235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfuro con la cadena ligera kappa (1'-213') [Homo sapiens V-KAPPA (IGKV1-5*03 (97.90%) - IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3(107'-213')]; dímeo (231-231'':234-234'')-bisdisulfuro Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 508 laprituximabum # laprituximab immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) ], chimeric monoclonal antibody; gamma1 heavy chain (1-448) [Mus musculus VH (IGHV1- 7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01 -IGKJ2*03) [6.3.9] (1'- 107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide laprituximab immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [Mus musculus VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV19- 93*01 - IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (228-228'':231-231'')- bisdisulfure. laprituximab inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB) ], anticuerpo monoclonal quimérico; WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 509 cadena pesada gamma1 (1-448) [Mus musculus VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218- 232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01 - IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro laprituximabum emtansinum # laprituximab emtansine immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [Mus musculus VH (IGHV1- 7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (228-228'':231-231'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane- 1-carboxylate (SMCC) linker forming a nonreducible thioether bond For the emtansine part, please refer to the document ''INN for pharmaceutical substances: Names for radicals, groups and others''*. laprituximab emtansine immunoglobuline G1-kappa, anti-[Homo sapiens EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1; Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 510 chaîne lourde gamma1 (1-448) [Mus musculus VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01- IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(N-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible Pour la partie emtansine, veuillez-vous référer au document ''INN for pharmaceutical substances: Names for radicals, groups and others''*. laprituximab emtansina inmunoglobulina G1-kappa, anti-[Homo sapiens EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM1; cadena pesada gamma1 (1-448) [Mus musculus VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218- 232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV19-93*01- IGKJ2*03) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro; conjugado, de 3 a 4 restos lisil por término medio, con el maitansinoide DM1 mediante el conector succinimidil- 4-(N-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible La fracción emtensina se pueden encontrar en el documento "'INN for pharmaceutical substances: Names for radicals, groups and others''*. WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 511 lenadogenum nolparvovecum # lenadogene nolparvovec a non-replicating single stranded DNA recombinant adeno- associated virus (rAAV) serotype 2 containing human wt MT-ND4 cDNA that encodes NADH Dehydrogenase subunit 4, under the control of the cytomegalovirus immediate early (CMVie) promoter in an intron-containing expression cassette (beta globin intron, HBB2), flanked by the viral inverted terminal repeats from AAV2/2. lénadogène nolparvovec vecteur viral adéno-associé de sérotype 2 recombinant (rAAV) non-répliquant, avec un ADN monocaténaire contenant le gène wt MT-ND4 codant pour la sous-unité 4 de la NADH déshydrogénase humaine, sous le contrôle d’un cytomégalovirus immédiat précoce dans un intron contenant la cassette d’expression (intron bêta-globine, HBB2), flanqué de répétitions inverses dérivées du virus adéno-associé de sérotype 2 lenadogén nolparvovec vector viral adeno-asociado de serotipo 2 recombinante (rAAV) no replicativo, con un ADN monocatenario que contiene el gen wt MT-ND4 que codifica para la subunidad 4 de la NADH deshidrogenasa humano, bajo el control de un promotor inmediato temprano del citomegalovirus en un intron que contiene el cassette de expresión (intron beta- globin, HBB2), flanqueado de repeticiones inversas derivadas del virus adeno-asociado del serotipo 2 leniolisibum leniolisib 1-[(3S)-3-({6-[6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl]- 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin- 4-yl}amino)pyrrolidin-1-yl]propan-1-one léniolisib 1-[(3S)-3-({6-[6-méthoxy-5-(trifluorométhyl)pyrimidin-3-yl]- 5,6,7,8-tétrahydropyrido[4,3-d]pyrimidin- 4-yl}amino)pyrrolidin-1-yl]propan-1-one leniolisib 1-[(3S)-3-({6-[6-metoxi-5-(trifluorometil)pirimidin-3-il]- 5,6,7,8-tetrahidropirido[4,3-d]pirimidin-4-il}amino)pirrolidin- 1-il]propan-1-ona C21H25F3N6O2 levoketoconazolum levoketoconazole 1-{4-[4-({(2S,4R)-2-(2,4-dichlorophenyl)-2-[(1H-imidazol- 1-yl)methyl]-1,3-dioxolan-4-yl}methoxy)phenyl]piperazin- 1-yl}ethan-1-one Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 512 lévokétoconazole 1-{4-[4-({(2S,4R)-2-(2,4-dichlorophényl)-2-[(1H-imidazol- 1-yl)méthyl]-1,3-dioxolan-4-yl}méthoxy)phényl]pipérazin- 1-yl}éthan-1-one levoketoconazol 1-{4-[4-({(2S,4R)-2-(2,4-diclorofenil)-2-[(1H-imidazol- 1-il)metil]-1,3-dioxolan-4-il}metoxi)fenil]piperazin-1-il}etan- 1-ona C26H28Cl2N4O4 lorlatinibum lorlatinib (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo- 10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile lorlatinib (10R)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo- 10,15,16,17-tétrahydro-2H-4,8-méthénopyrazolo[4,3- h][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile lorlatinib (10R)-7-amino-12-fluoro-2,10,16-trimetil-15-oxo- 10,15,16,17-tetrahidro-2H-4,8-metenopirazolo[4,3- h][2,5,11]benzoxadiazaciclotetradecina-3-carbonitrilo C21H19FN6O2 lumateperonum lumateperone 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl- 2,3,6b,9,10,10a-hexahydro- 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)- yl]butan-1-one lumatépérone 1-(4-fluorophényl)-4-[(6bR,10aS)-3-méthyl- 2,3,6b,9,10,10a-hexahydro- 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]- butan-1-one lumateperona 1-(4-fluorofenil)-4-[(6bR,10aS)-3-metil-2,3,6b,9,10,10a- hexahidro-1H-pirido[3',4':4,5]pirrolo[1,2,3-de]quinoxalin- 8(7H)-il]butan-1-ona WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 513 C24H28FN3O mesmulogenum ancovacivecum # mesmulogene ancovacivec a non-replicating recombinant vaccinia virus, based on the Modified Vaccinia Virus Ankara (MVA) strain, carrying sequences coding for the expression of the human Mucine 1 (MUC1) antigen and human Interleukin 2 (IL2), under the control of pH5R and p7.5 vaccinia promoters, respectively. mesmulogène ancovacivec vecteur viral recombinant non-répliquant de la vaccine, dérivé du virus de la vaccine modifié Ankara, contenant les séquences d’ADN codant pour l’expression de l’antigène de la Mucine 1 et de l’interleukine 2 humaine, sous le contrôle des promoteurs pH5R et p7.5, respectivement mesmulogén ancovacivec vector viral recombinante no replicativo de la vacuna, derivado de la cepa del virus de la vacuna modificada Ankara, que contiene las secuencias del ADN que codifica para la expresión del antígeno de la Mucina 1 (MUC1) y de la interleukina 2 humana (IL2), bajo el control de los promotores vaccinia pH5R y p7.5, respectivamente mipeginterferonum alfa-2b # mipeginterferon alfa-2b N2.1,N6.Lys-oligo(N-{2-[ω-methoxypoly(oxyethylene)-α- yl]acetyl}-N-[α-methylpoly(oxyethylene)-ω-yl]glycyl)human interferon alpha-2b, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6), the protein part being produced in Pichia pastoris (Komagataella pastoris) The relative molecular mass of the polyethylene glycol part can be indicated after the INN, for example: mipeginterferon alfa-2b (40 kDa) mipèginterféron alfa-2b N2.1,N6.Lys-oligo(N-{2-[ω-méthoxypoly(oxyéthylène)-α- yl]acétyl}-N-[α-méthylpoly(oxyéthylène)-ω- yl]glycyl)interféron alpha-2b humain, une moyenne de 5 azotes parmi les 11 (un N-terminal et 10 lysines N6) sont substitués, la partie protéique étant produite par Pichia pastoris (Komagataella pastoris) La masse molaire de la partie polyéthylène glycol peut être indiquée après la DCI, par exemple: mipèginterféron alfa- 2b (40 kDa) Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 514 mipeginterferón alfa-2b N2.1,N6.Lys-oligo(N-{2-[ω-metoxipoli(oxietileno)-α-il]acetil}- N-[α-metilpoli(oxietileno)-ω-il]glicil)interferón alpha-2b humano, con una media de 5 grupos amino sustituidos entre los 11 (un N-terminal y 10 lisinas N6), la parte proteica es producida por Pichia pastoris (Komagataella pastoris) La masa molar de la parte polietilen glicol puede ser indicada después de la DCI, por ejemplo: mipeginterferón alfa-2b (40 kDa). R =HS CO2H HNHR H2N CO2H H NHR Sequence / Séquence / Secuencia CDLPQTHSLG SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA 50 ETIPVLHEMI QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI 100 QGVGVTETPL MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS 150 FSLSTNLQES LRSKE 165 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 1-98 29-138 Potential modified residues / Résidus potentiellement modifiés / Restos potencialmente modificados C 1 K 31, 49, 70, 83, 112, 121, 131, 133, 134, 164 N O C O O H3C H3CO O n n mirvetuximabum # mirvetuximab immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], chimeric monoclonal antibody; gamma1 heavy chain (1-447) [Mus musculus VH (IGHV1- 37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with kappa light chain (1'-218') [Mus musculus V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'- 111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide mirvétuximab immunoglobuline G1-kappa, anti-[Homo sapiens FOLR1 (récepteur 1 du folate, récepteur alpha du folate, FR-alpha, protéine de l’adulte liant le folate, FBP, antigène MOv18 associé à des tumeurs ovariennes)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-447) [Mus musculus VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [Mus musculus V-KAPPA (IGKV3- 9*01 -IGKJ2*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dimère (227-227'':230-230'')- bisdisulfure WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 515 mirvetuximab inmunoglobulina G1-kappa, anti-[Homo sapiens FOLR1 (receptor 1 de folato, receptor alfa de folato, FR-alpha, proteína del adulto que liga el folato, FBP, antígeno Mov18 asociado a tumores ováricos)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-447) [Mus musculus VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217- 231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [Mus musculus V-KAPPA (IGKV3-9*01 - IGKJ2*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; dímero (227-227'':230-230'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VVKPGASVKI SCKASGYTFT GYFMNWVKQS PGQSLEWIGR 50 IHPYDGDTFY NQKFQGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD 100 GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200 CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350 TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447 Light chain / Chaîne légère / Cadena ligera DIVLTQSPLS LAVSLGQPAI ISCKASQSVS FAGTSLMHWY HQKPGQQPRL 50 LIYRASNLEA GVPDRFSGSG SKTDFTLTIS PVEAEDAATY YCQQSREYPY 100 TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200 THQGLSSPVT KSFNRGEC 218 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 145-201 262-322 368-426 22''-96'' 145''-201'' 262''-322'' 368''-426'' Intra-L (C23-C104) 23'-92' 138'-198' 23'''-92''' 138'''-198''' Inter-H-L (h 5-CL 126) 221-218' 221''-218''' Inter-H-H (h 11, h 14) 227-227'' 230-230'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 298, 298'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados mizagliflozinum mizagliflozin 3-{[3-(4-{[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)- 1H-pyrazol-4-yl]methyl}-3-methylphenoxy)propyl]amino}- 2,2-dimethylpropanamide mizagliflozine 3-{[3-(4-{[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)- 1H-pyrazol-4-yl]méthyl}-3-méthylphénoxy)propyl]amino}- 2,2-diméthylpropanamide mizagliflozina 3-{[3-(4-{[3-(β-D-glucopiranosiloxi)-5-(propan-2-il)- 1H-pirazol-4-il]metil}-3-metilfenoxi)propil]amino}- 2,2-dimetilpropanamida Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 516 C28H44N4O8 nafithromycinum nafithromycin (3R,31Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-ethyl- 8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo- N'-{(1S)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]ethoxy}- 9-{[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo- hexopyranosyl]oxy}tetradecahy-dro-2H-furo[2,3- c]oxacyclotetradecine-3-carboximidamide nafithromycine (3R,31Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-éthyl- 8-méthoxy-4,6,8,10,12,15a-hexaméthyl-2,5,11,13-tétraoxo- N'-{(1S)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]éthoxy}- 9-{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo- hexopyranosyl]oxy}tétradecahy-dro-2H-furo[2,3- c]oxacyclotétradécine-3-carboximidamide nafitromicina (3R,31Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-etil- 8-metoxi-4,6,8,10,12,15a-hexametil-2,5,11,13-tetraoxo- N'-{(1S)-1-[5-(piridin-2-il)-1,3,4-tiadiazol-2-il]etoxi}-9-{[3,4,6- tridesoxi-3-(dimetilamino)-β-D-xilo- hexopiranosil]oxi}tetradecahidro-2H-furo[2,3- c]oxaciclotetradecina-3-carboximidamida C42H62N6O11S O H CH3 O CH3 H CH3 O OO H CH3 H H H3C H3CO H3C CH3 H O H O H3C N O OH CH3 H3C H2N N H O S N N N CH3H naratuximabum # naratuximab immunoglobulin G1-kappa, anti-[Homo sapiens CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody; WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 517 gamma1 heavy chain (1-444) [Mus musculus VH (IGHV2- 3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'- 107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide naratuximab immunoglobuline G1-kappa, anti-[Homo sapiens CD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-444) [Mus musculus VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 - IGKJ1*01)[6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure naratuximab inmunoglobulina G1-kappa, anti-[Homo sapiens CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoconal quimérico; cadena pesada gamma1 (1-444) [Mus musculus VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214- 228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 - IGKJ1*01)[6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 518 naratuximabum emtansinum # naratuximab emtansine immunoglobulin G1-kappa, anti-[Homo sapiensCD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-444) [Mus musculus VH (IGHV2- 3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'- 107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane- 1-carboxylate (SMCC) linker forming a nonreducible thioether bond For the emtansine part, please refer to the document ''INN for pharmaceutical substances: Names for radicals, groups and others''*. naratuximab emtansine immunoglobuline G1-kappa, anti-[Homo sapiensCD37 (tétraspanine-26, TSPAN26)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-444) [Mus musculus VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV12- 46*01 - IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')- bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl- 4-(N-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible Pour la partie emtansine, veuillez-vous référer au document ''INN for pharmaceutical substances: Names for radicals, groups and others''*. naratuximab emtansina inmunoglobulina G1-kappa, anti-[Homo sapiensCD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal quimérico conjugado con maitansinoide DM1; cadena pesada gamma1 (1-444) [Mus musculus VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214- 228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro; conjugado, en una media de 3 a 4 restos lisil, con maitansinoide DM1 mediante un conector succinimidil -4-(N-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible La fracción emtensina se pueden encontrar en el documento "'INN for pharmaceutical substances: Names for radicals, groups and others''*. WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 519 navamepentum navamepent propan-2-yl (5S,8E,10E,12R)-5,12-dihydroxypentadeca- 8,10-diene-6,14-diynoate navamépent (5S,8E,10E,12R)-5,12-dihydroxypentadéca-8,10-diène- 6,14-diynoate de propan-2-yle navamepent (5S,8E,10E,12R)-5,12-dihidroxipentadeca-8,10-dieno- 6,14-diinoato de propan-2-ilo C18H24O4 navicixizumabum # navicixizumab immunoglobulin G2-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] and anti-[Homo sapiens VEGFA (vascular endothelial growth factor A,VEGF-A, VEGF)], humanized and chimeric monoclonal antibody, bispecific; Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 520 gamma2 heavy chain, humanized anti-DLL4 (1-445) [humanized VH (Homo sapiens IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230- 338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)],(133-218')-disulfide with kappa light chain, chimeric (1’-218’) [chimeric V-KAPPA (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; gamma2 heavy chain, humanized anti-VEGFA (1-447) [humanized VH (Homo sapiens IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232- 340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfide with kappa light chain, chimeric (1'''-218''') [chimeric V-KAPPA (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'''-111''') -Homo sapiens IGKC*01, Km3 (112'''-218''')]; dimer (221-223":222-224":225-227":228-230")- tetrakisdisulfide navicixizumab immunoglobuline G2-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] et anti-[Homo sapiens VEGFA (facteur de croissance A de l’endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé et chimérique, bispécifique; chaîne lourde gamma2, humanisée anti-DLL4 (1-445) [VH humanisé (Homo sapiens IGHV1-18*01 (84.70%) -(IGHD)- IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG2*01 (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfure avec la chaîne légère kappa, chimérique (1’-218’) [V-KAPPA chimérique (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'-218')]; chaîne lourde gamma2, humanisée anti-VEGFA (1-447) [VH humanisé (Homo sapiens IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445) E13>K (357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfure avec la chaîne légère kappa, chimérique (1'''-218''') [V-KAPPA chimérique (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'''-111''') -Homo sapiens IGKC*01, Km3 (112'''-218''')]; dimère (221-223":222-224":225- 227":228-230")-tétrakisdisulfure navicixizumab inmunoglobulina G2-kappa, anti-[Homo sapiens DLL4 (delta-like 4)] y anti-[Homo sapiens VEGFA (factor de crecimiento A del endotelio vascular,VEGF-A, VEGF)], anticuerpo humanizado y quimérico, biespecífico; WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 521 cadena pesada gamma2, humanizada anti-DLL4 (1-445) [VH humanizado (Homo sapiens IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG2*01 (CH1 (120-217), bisagra (218-229), CH2 (230- 338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfuro con la cadena ligera kappa, quimérica (1’-218’) [V-KAPPA quimérico (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01, Km3 (112'- 218')]; cadena pesada gamma2, humanizada anti-VEGFA (1-447) [VH humanizado (Homo sapiens IGHV1-46*01 (83.30%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CH1(122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfuro con la cadena ligera kappa, quimérica (1'''-218''') [V- KAPPA quimérico (Mus musculus IGKV3-2*01 -Homo sapiens IGKJ1*01) [10.3.9] (1'''-111''') -Homo sapiens IGKC*01, Km3 (112'''-218''')]; dímero (221-223":222- 224":225-227":228-230")-tetrakisdisulfuro nazartinibum nazartinib N-(7-chloro-1-{(3R)-1-[(2E)-4-(dimethylamino)but- 2-enoyl]azepan-3-yl}-1H-benzimidazol-2-yl)- 2-methylpyridine-4-carboxamide nazartinib N-(7-chloro-1-{(3R)-1-[(2E)-4-(diméthylamino)but- 2-énoyl]azépan-3-yl}-1H-benzimidazol-2-yl)- 2-méthylpyridine-4-carboxamide Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 522 nazartinib N-(7-cloro-1-{(3R)-1-[(2E)-4-(dimetilamino)but- 2-enoil]azepan-3-il}-1H-benzimidazol-2-il)-2-metilpiridina- 4-carboxamida C26H31ClN6O2 N N NH O N H N O Cl N CH3 CH3 CH3 nicodicosapentum nicodicosapent N-{2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17- pentaenamido]ethyl}pyridine-3-carboxamide nicodicosapent N-{2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17- pentaénamido]éthyl}pyridine-3-carboxamide nicodicosapent N-{2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17- pentaenamido]etil}piridina-3-carboxamida C28H39N3O2 nolasibanum nolasiban [(2S,4Z)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin- 1-yl](2'-methyl[1,1'-biphenyl]-4-yl)methanone nolasiban [(2S,4Z)-2-(hydroxyméthyl)-4-(méthoxyimino)pyrrolidin- 1-yl](2'-méthyl[1,1'-biphényl]-4-yl)méthanone nolasibán (2S,4Z)-2-(hidroximetil)-4-(metoxiimino)pirrolidin-1-il](2'- metil[1,1'-bifenil]-4-il)metanona C20H22N2O3 NCH3 O H OH N O CH3 oliceridinum oliceridine N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-(pyridin- 2-yl)-6-oxaspiro[4.5]decan-9-yl]ethan-1-amine WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 523 olicéridine N-[(3-méthoxythiophén-2-yl)méthyl]-2-[(9R)-9-(pyridin- 2-yl)-6-oxaspiro[4.5]décan-9-yl]éthan-1-amine oliceridina N-[(3-metoxitiofen-2-il)metil]-2-[(9R)-9-(piridin-2-il)- 6-oxaspiro[4.5]decan-9-il]etan-1-amina C22H30N2O2S olmutinibum olmutinib N-[3-({2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2- d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide olmutinib N-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]thiéno[3,2- d]pyrimidin-4-yl}oxy)phényl]prop-2-énamide olmutinib N-[3-({2-[4-(4-metilpiperazina-1-il)anilino]tieno[3,2- d]pirimidin-4-il}oxi)fenil]prop-2-enamida C26H26N6O2S olumacostatum glasaretilum olumacostat glasaretil 2-[(2-ethoxy-2-oxoethyl)(methyl)amino]-2-oxoethyl 5- (tetradecyloxy)furan-2-carboxylate olumacostat glasarétil 5-(tétradécyloxy)furane-2-carboxylate de 2-[(2-éthoxy-2- oxoéthyl)(méthyl)amino]-2-oxoéthyle olumacostat glasaretilo 5-(tetradeciloxi)furan-2-carboxilato de 2-[(2-etoxi-2- oxoetil)(metil)amino]-2-oxoetilo C26H43NO7 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 524 omidenepagum omidenepag ({6-[(N-{[4-(1H-pyrazol-1-yl)phenyl]methyl}pyridine- 3-sulfonamido)methyl]pyridin-2-yl}amino)acetic acid omidénépag acide ({6-[(N-{[4-(1H-pyrazol-1-yl)phényl]méthyl}pyridine- 3-sulfonamido)méthyl]pyridin-2-yl}amino)acétique omidenepag ácido ({6-[(N-{[4-(1H-pirazol-1-il)fenil]metil}piridina- 3-sulfonamido)metil]piridin-2-il}amino)acético C23H22N6O4S N N S H N CO2H NN O O N oteseconazolum oteseconazole (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,3,4- tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin- 2-yl}propan-2-ol otéséconazole (2R)-2-(2,4-difluorophényl)-1,1-difluoro-3-(1H-1,2,3,4- tétrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroéthoxy)phényl]pyridin- 2-yl}propan-2-ol oteseconazol (2R)-2-(2,4-difluorofenil)-1,1-difluoro-3-(1H-1,2,3,4-tetrazol- 1-il)-1-{5-[4-(2,2,2-trifluoroetoxi)fenil]piridin-2-il}propan-2-ol C23H16F7N5O2 pibrentasvirum pibrentasvir dimethyl N,N'-([(2R,5R)-1-{3,5-difluoro-4-[4-(4- fluorophenyl)piperidin-1-yl]phenyl}pyrrolidine- 2,5-diyl]bis{(6-fluoro-1H-benzimidazole-5,2-diyl)[(2S)- pyrrolidine-2,1-diyl][(2S,3R)-3-methoxy-1-oxobutane- 1,2-diyl]})dicarbamate WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 525 pibrentasvir N,N'-([(2R,5R)-1-{3,5-difluoro-4-[4-(4- fluorophényl)pipéridin-1-yl]phényl}pyrrolidine- 2,5-diyl]bis{(6-fluoro-1H-benzimidazole-5,2-diyl)[(2S)- pyrrolidine-2,1-diyl][(2S,3R)-3-méthoxy-1-oxobutane- 1,2-diyl]})dicarbamate de diméthyle pibrentasvir N,N'-([(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin- 1-il]fenil}pirrolidina-2,5-diil]bis{(6-fluoro-1H-benzimidazol- 5,2-diil)[(2S)-pirrolidina-2,1-diil][(2S,3R)-3-metoxi- 1-oxobutano-1,2-diil]})dicarbamato de dimetil C57H65F6N10O8 prexasertibum prexasertib 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol- 3-yl}amino)pyrazine-2-carbonitrile prexasertib 5-({5-[2-(3-aminopropoxy)-6-méthoxyphényl]-1H-pyrazol- 3-yl}amino)pyrazine-2-carbonitrile prexasertib 5-({5-[2-(3-aminopropoxi)-6-metoxifenil]-1H-pirazol- 3-il}amino)pirazina-2-carbonitrilo C18H19N7O2 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 526 prexigebersenum prexigebersen 2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')- 2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl- (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')- 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')- 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')- thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')- 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')- thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidine prexigébersen 2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')- 2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl- (3'→5')-thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')- 2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')- 2'-déoxyguanylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')- thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')- 2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')- thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidine prexigebersén 2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiadenilil- (3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')- 2'-desoxiguanilil-(3'→5')-2'-desoxiguanilil-(3'→5')- 2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')- 2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanilil- (3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')- timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidina C177H224N63O110P17 (3'-5')d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C) prezalumabum # prezalumab immunoglobulin G2-kappa, anti-[Homo sapiens ICOSL (inducible T-cell co-stimulatory ligand, B7 homologue 2, B7H2, B7-H2, B7-related protein 1, B7RP1, B7RP-1, CD275)], Homo sapiens monoclonal antibody; gamma2 heavy chain (1-447) [Homo sapiens VH (IGHV3- 7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) - IGHG2*01, G2m.. (CH1 (122-219), hinge (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (223- 223'':224-224'':227-227'':230-230'')-tetrakisdisulfide prézalumab immunoglobuline G2-kappa, anti-[Homo sapiens ICOSL (ligand inductible co-stimulateur des cellules T, homologue 2 du B7, B7H2, B7-H2, protéine 1 apparentée au B7, B7RP1, B7RP-1, CD275)], Homo sapiens anticorps monoclonal; chaîne lourde gamma2 (1-447) [Homo sapiens VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1- 121) -IGHG2*01, G2m.. (CH1 (122-219), charnière (220- 231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'- 214')]; dimère (223-223'':224-224'':227-227'':230-230'')- tétrakisdisulfure WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 527 prezalumab inmunoglobulina G2-kappa, anti-[Homo sapiens ICOSL (ligando inducible co-estimulador de las células T, B7 homólogo 2, B7H2, B7-H2, proteína 1 relacionada con la B7, B7RP1, B7RP-1, CD275)], Homo sapiens anticuerpo monoclonal; cadena pesada gamma2 (1-447) [Homo sapiens VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1- 121) -IGHG2*01, G2m.. (CH1 (122-219), bisagra (220- 231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'- 214')]; dímero (223-223'':224-224'':227-227'':230-230'')- tetrakisdisulfuro redaporfinum redaporfin 3,3',3'',3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20- tetrayl)tetrakis(2,4-difluoro-N-methylbenzenesulfonamide) rédaporfine 3,3',3'',3'''-(7,8,17,18-tétrahydroporphyrin-5,10,15,20- tétrayl)tétrakis(2,4-difluoro-N-méthylbenzènesulfonamide) redaporfina 3,3',3'',3'''-(7,8,17,18-tetrahidroporfirin-5,10,15,20- tetrail)tetrakis(2,4-difluoro-N-metilbencenosulfonamida) Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 528 C48H38F8N8O8S4 NH N HNN S S S S F F FF F F F F NH H3C N H CH3 HN CH3 H N H3C OO O O O O O O refanezumabum # refanezumab immunoglobulin G1-kappa, anti-[Homo sapiens MAG (myelin associated glycoprotein, sialic acid binding Ig-like lectin 4A, SIGLEC4A, SIGLEC-4A)], humanized monoclonal antibody; gamma1 heavy chain (1-456) [humanized VH (Homo sapiens IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -Homo sapiens IGHG1*01, G1m17,1 (CH1 (127-224), hinge (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127- 456)], (229-219')-disulfide with kappa light chain (1’-219’) [humanized V-KAPPA (Homo sapiens IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -Homo sapiens IGKC*01, Km3 (113'-219')]; dimer (235-235":238-238")- bisdisulfide réfanézumab immunoglobuline G1-kappa, anti-[Homo sapiens MAG (glycoprotéine associée à la myéline, lectine 4A Ig-like liant l’acide sialique, SIGLEC4A, SIGLEC-4A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-456) [humanisé VH (Homo sapiens IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -Homo sapiens IGHG1*01, G1m17,1 (CH1 (127-224), charnière (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127- 456)], (229-219')- disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -Homo sapiens IGKC*01, Km3 (113'-219')]; dimère (235-235":238-238")- bisdisulfure WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 529 refanezumab inmunoglobulina G1-kappa, anti-[Homo sapiens MAG (glicoproteína asociada a la mielina, lectina de tipo inmunoglobulina 4A que se une al ácido siálico, SIGLEC4A, SIGLEC-4A)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-456) [VH humanizado (Homo sapiens IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -Homo sapiens IGHG1*01, G1m17,1 (CH1 (127-224), bisagra (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127- 456)], (229-219')-disulfuro con la cadena ligera kappa (1’- 219’) [V-KAPPA humanizado (Homo sapiens IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -Homo sapiens IGKC*01, Km3 (113'-219')]; dímero (235-235":238-238")- bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGSE LKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW 50 INTYTGEPTY ADDFTGRFVF SLDTSVSTAY LQISSLKAED TAVYYCARNP 100 INYYGINYEG YVMDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150 LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200 SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELAGAPSVF 250 LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350 QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400 KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450 SLSPGK 456 Light chain / Chaîne légère / Cadena ligera DIVMTQSPDS LAVSLGERAT INCKSSHSVL YSSNQKNYLA WYQQKPGQPP 50 KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCHQYLSS 100 LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150 VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200 VTHQGLSSPV TKSFNRGEC 219 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 153-209 270-330 376-434 22''-96'' 153''-209'' 270''-330'' 376''-434'' Intra-L (C23-C104) 23'-94' 139'-199' 23'''-94''' 139'''-199''' Inter-H-L (h 5-CL 126) 229-219' 229''-219''' Inter-H-H (h 11, h 14) 235-235'' 238-238'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 306, 306'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados revefenacinum revefenacin 1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]- N-methylbenzamido}ethyl)piperidin-4-yl N-([1,1'-biphenyl]- 2-yl)carbamate révéfénacine N-([1,1'-biphényl]-2-yl)carbamate de 1-(2-{4-[(4-carbamoylpipéridin-1-yl)méthyl]- N-méthylbenzamido}éthyl)pipéridin-4-yle revefenacina N-([1,1'-bifenil]-2-il)carbamato de 1-(2-{4-[(4-carbamoilpiperidin-1-il)metil]- N-metilbenzamida}etil)piperidin-4-il Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 530 C35H43N5O4 N O H N O N H3C O N O NH2 rivabazumabum # rivabazumab immunoglobulin Fab' G1-kappa, anti-[Pseudomonas aeruginosa type III secretion system (TTSS) PcrV protein], humanized monoclonal antibody; gamma1 heavy chain fragment VH-(CH1-hinge) (1-238) [humanized VH (Homo sapiens IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) -Homo sapiens IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237), CH2 (238)) (125-238)], noncovalently associated with kappa light chain (1’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') - Homo sapiens IGKC*01 C126>S (214') (108'-214')] rivabazumab immunoglobuline Fab' G1-kappa, anti-[protéine PcrV du système de sécrétion type III (TTSS) de Pseudomonas aeruginosa], anticorps monoclonal humanisé; fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-238) [VH humanisé (Homo sapiens IGHV3-30*06 (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) -Homo sapiens IGHG1*01 (CH1 (125-222), charnière C5>S (227) (223-237), CH2 (238)) (125-238)], associé de manière non covalente avec la chaîne légère kappa (1’-214’) [V-KAPPA humanisé (Homo sapiens IGKV1-5*01 (84.60%) - IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 C126>S (214') (108'-214')] rivabazumab inmunoglobulina Fab' G1-kappa, anti-[proteína PcrV del sistema de secreción tipo III (TTSS) de Pseudomonas aeruginosa], anticuerpo monoclonal humanizado; fragmento VH-(CH1-bisagra) de la cadena pesada gamma1 (1-238) [VH humanizado (Homo sapiens IGHV3- 30*06 (92.90%) -(IGHD) -IGHJ6*01) [8.8.17] (1-124) - Homo sapiens IGHG1*01 (CH1 (125-222), bisagra C5>S (227) (223-237), CH2 (238)) (125-238)], asociado de modo nocovalente con la cadena ligera kappa (1’-214’) [V- KAPPA humanizado (Homo sapiens IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 C126>S (214') (108'-214')] WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 531 ruclosporinum ruclosporin 8-[(2R)-N-methyl-2-[2-(4- morpholinyl)ethoxy]glycine]cyclosporin A: cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl- L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-3-hydroxy- N,4-dimethyl-L-2-aminooct-6-enoyl-L-2-aminobutanoyl- (2R)-N-methyl-2-[2-(morpholin-4-yl)ethoxy]glycyl-N-methyl- L-leucyl-L-valyl-N-methyl-L-leucyl] ruclosporine 8-[(2R)-N-méthyl-2-[2-(4- morpholinyl)éthoxy]glycine]cyclosporine A: cyclo[L-alanyl-D-alanyl-N-méthyl-L-leucyl-N-méthyl- L-leucyl-N-méthyl-L-valyl-(3R,4R,6E)-3-hydroxy- N,4-diméthyl-L-2-aminooct-6-énoyl-L-2-aminobutanoyl- (2R)-N-méthyl-2-[2-(morpholin-4-yl)éthoxy]glycyl-N-méthyl- L-leucyl-L-valyl-N-méthyl-L-leucyl] ruclosporina 8-[(2R)-N-metil-2-[2-(4-morfolinil)etoxi]glicina]ciclosporina A: ciclo[L-alanil-D-alanil-N-metil-L-leucil-N-metil-L-leucil- N-metil-L-valil-(3R,4R,6E)-3-hidroxi-N,4-dimetil- L-2-aminooct-6-enoil-L-2-aminobutanoil-(2R)-N-metil- 2-[2-(morfolin-4-il)etoxi]glicil-N-metil-L-leucil-L-valil-N-metil- L-leucil] C68H122N12O14 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 532 ruzasvirum ruzasvir dimethyl N,N'-([(6S)-6-(2-cyclopropyl-1,3-thiazol-5-yl)- 1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine- 3,10-diyl]bis{(1H-imidazole-4,2-diyl)[(2S)-pyrrolidine- 2,1-diyl][(2S)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate ruzasvir N,N'-([(6S)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro- 6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{(1H- imidazole-4,2-diyl)[(2S)-pyrrolidine-2,1-diyl][(2S)-3-méthyl- 1-oxobutane-1,2-diyl]})dicarbamate de diméthyle ruzasvir N,N'-([(6S)-6-(2-ciclopropil-1,3-tiazol-5-il)-1-fluoro- 6H-indolo[1,2-c][1,3]benzoxazina-3,10-diil]bis{(1H- imidazol-4,2-diil)[(2S)-pirrolidina-2,1-diil][(2S)-3-metil- 1-oxobutano-1,2-diil]})dicarbamato de dimetilo C49H55FN10O7S satoreotidum trizoxetanum satoreotide trizoxetan S2,S7-cyclo[N-{(4RS)-4-[4,7-bis(carboxymethyl)- 1,4,7-triazonan-1-yl]-4-carboxybutanoyl}-4-chloro- L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane- 4-carb-oxamido]-L-phenylalanyl-4-(carbamoylamino)- D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl- D-tyrosinamide] satoréotide trizoxétan S2,S7-cyclo[N-{(4RS)-4-[4,7-bis(carboxyméthyl)- 1,4,7-triazonan-1-yl]-4-carboxybutanoyl}-4-chloro- L-phénylalanyl-D-cystéinyl-4-[(4S)-2,6-dioxo-1,3-diazinane- 4-carb-oxamido]-L-phénylalanyl-4-(carbamoylamino)- D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéinyl- D-tyrosinamide] satoreotida trizoxetán S2,S7-ciclo[N-{(4RS)-4-[4,7-bis(carboximetil)- 1,4,7-triazonan-1-il]-4-carboxibutanoil}-4-cloro-L-fenilalanil- D-cisteinil-4-[(4S)-2,6-dioxo-1,3-diazinano-4-carboxamido]- L-fenilalanyl-4-(carbamoilamino)-D-fenilalanil-L-lisil- L-treonil-L-cisteinil-D-tirosinamida] WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 533 C73H95ClN18O21S2 seviteronelum seviteronel (1S)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl- 1-(1H-1,2,3-triazole-4-yl)propan-1-ol sevitéronel (1S)-1-[6,7-bis(difluorométhoxy)naphtalén-2-yl]-2-méthyl- 1-(1H-1,2,3-triazole-4-yl)propan-1-ol seviteronel (1S)-1-[6,7-bis(difluorometoxi)naftalen-2-il]-2-metil- 1-(1H-1,2,3-triazol-4-il)propan-1-ol C18H17F4N3O3 sitravatinibum sitravatinib N-(3-fluoro-4-{[2-(5-{[(2- methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2- b]pyridin-7-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane- 1,1-dicarboxamide sitravatinib N-(3-fluoro-4-{[2-(5-{[(2- méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2- b]pyridin-7-yl]oxy}phényl)-N'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide sitravatinib N-(3-fluoro-4-{[2-(5-{[(2-metoxietil)amino]metil}piridin- 2-il)tieno[3,2-b]piridin-7-il]oxi}fenil)- N'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida C33H29F2N5O4S Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 534 talinexomerum talinexomer poly[(prop-2-enoic acid)-co-{2-ethyl-2-[(prop- 2-enoyloxy)methyl]propane-1,3-diyl di(prop-2-enoate)}] talinexomère poly[(acide prop-2-énoïque)-co-{di(prop-2-énoate) de 2-éthyl-2-[(prop-2-énoyloxy)méthyl]propane-1,3-diyle}] talinexómero poli[(ácido prop-2-enoico)-co-{di(prop-2-enoato de 2-etil- 2-[(prop-2-enoiloxi)metil]propano-1,3-diilo}] [[C15H20O6]x . [C3H4O2]y]n y/x ≈ 1000 tamtuvetmabum # tamtuvetmab immunoglobulin G2_V-kappa-C-lambda, anti-[Homo sapiens CD52], caninized monoclonal antibody; gamma2 heavy chain chimeric (1-456) [chimeric VH (Rattus norvegicus IGHV7S6*01 (97.00%) -(IGHD) -Canis lupus familiaris IGHJ-E2RCC8) [8.10.12] (1-121) -Canis lupus familiaris IGHG2*02 (CH1 (122-219), hinge (220- 237), CH2 (238-347), CH3 (348-454), CHS (455- 456))(122-456)], (136-212')-disulfide with V-kappa- C-lambda light chain chimeric (1'-213') [Rattus norvegicus V-KAPPA (Rattus norvegicus IGKV22S7 (93.70%) - IGKJ1*01) [6.3.9] (1'-107') -Canis lupus familiaris IGLC1S1*01 V45.3>I (156) (108'-213')]; dimer (233- 233'':236-236'')-bisdisulfide tamtuvetmab immunoglobuline G2_V-kappa-C-lambda, anti-[Homo sapiens CD52], anticorps monoclonal caninisé; chaîne lourde gamma2 chimérique (1-456) [VH chimérique (Rattus norvegicus IGHV7S6*01 (97.00%) -(IGHD) -Canis lupus familiaris IGHJ-E2RCC8) [8.10.12] (1-121) -Canis lupus familiaris IGHG2*02 (CH1 (122-219), charnière (220- 237), CH2 (238-347), CH3 (348-454), CHS (455-456)) (122-456)], (136-212')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-213') [Rattus norvegicus V-KAPPA (Rattus norvegicus IGKV22S7 (93.70%) - IGKJ1*01) [6.3.9] (1'-107') -Canis lupus familiaris IGLC1S1*01 V45.3>I (156) (108'-213')]; dimère (233- 233'':236-236'')-bisdisulfure tamtuvetmab inmunoglobulina G2_V-kappa-C-lambda, anti-[Homo sapiens CD52], anticuerpo monoclonal caninizado; WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 535 cadena pesada gamma2 quimérica (1-456) [VH quimérico (Rattus norvegicus IGHV7S6*01 (97.00%) -(IGHD) -Canis lupus familiaris IGHJ-E2RCC8) [8.10.12] (1-121) -Canis lupus familiaris IGHG2*02 (CH1 (122-219), bisagra (220- 237), CH2 (238-347), CH3 (348-454), CHS (455- 456))(122-456)], (136-212')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-213') [Rattus norvegicus V-KAPPA (Rattus norvegicus IGKV22S7 (93.70%) - IGKJ1*01) [6.3.9] (1'-107') -Canis lupus familiaris IGLC1S1*01 V45.3>I (156) (108'-213')]; dímero (233- 233'':236-236'')-bisdisulfuro tarloxotinibi bromidum tarloxotinib bromide (2E)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin- 6-yl]amino}-N,N-dimethyl-N-[(1-methyl-4-nitro-1H-imidazol- 5-yl)methyl]-4-oxobut-2-en-1-aminium bromide bromure de tarloxotinib bromure de (2E)-4-{[4-(3-bromo-4-chloroanilino)pyrido[3,4- d]pyrimidin-6-yl]amino}-N,N-diméthyl-N-[(1-méthyl-4-nitro- 1H-imidazol-5-yl)méthyl]-4-oxobut-2-én-1-aminium bromuro de tarloxotinib bromuro de (2E)-4-{[4-(3-bromo-4-cloroanilino)pirido[3,4- d]pirimidin-6-il]amino}-N,N-dimetil-N-[(1-metil-4-nitro-1H- imidazol-5-il)metil]-4-oxobut-2-en-1-aminium C24H24Br2ClN9O3 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 536 tenalisibum tenalisib 3-(3-fluorophenyl)-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}- 4H-1-benzopyran-4-one ténalisib 3-(3-fluorophényl)-2-{(1S)-1-[(7H-purin-6-yl)amino]propyl}- 4H-1-benzopyran-4-one tenalisib 3-(3-fluorofenil)-2-{(1S)-1-[(7H-purin-6-il)amino]propil}-4H- 1-benzopiran-4-ona C23H18FN5O2 O O N H N N N HN H F H3C tetrodotoxinum tetrodotoxin (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino- 12-(hydroxymethyl)-1,4,4a,5,9,10-hexahydro-7H-5,9:7,10a- dimethano[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12- pentol tétrodotoxine (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino- 12-(hydroxyméthyl)-1,4,4a,5,9,10-hexahydro-7H-5,9:7,10a- diméthano[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12- pentol tetrodotoxina (4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-amino- 12-(hidroximetil)-1,4,4a,5,9,10-hexahidro-7H-5,9:7,10a- dimetano[1,3]dioxocino[6,5-d]pirimidina-4,7,10,11,12- pentol C11H17N3O8 tezacaftorum tezacaftor 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3- dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan- 2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 537 tezacaftor 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3- dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan- 2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide tezacaftor 1-(2,2-difluoro-2H-1,3-benzodioxol-5-il)-N-{1-[(2R)-2,3- dihidroxipropil]-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)- 1H-indol-5-il}ciclopropano-1-carboxamida C26H27F3N2O6 timolumabum # timolumab immunoglobulin G4-kappa, anti-[Homo sapiens AOC3 (amine oxidase copper containing 3 (EC 1.4.3.21), vascular adhesion protein 1, VAP1, VAP-1)],Homo sapiens monoclonal antibody; gamma4 heavy chain (1-444) [Homo sapiens VH (IGHV3- 30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) - IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443- 444)) (118-444)], (131-214')-disulfide with kappa light chain (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'- 214')]; dimer (223-223":226-226")-bisdisulfide timolumab immunoglobuline G4-kappa, anti-[Homo sapiens AOC3 (amine oxydase à cuivre 3 (EC 1.4.3.21), VAP-1, protéine d’adhérence vasculaire 1, VAP1, VAP-1)], Homo sapiens anticorps monoclonal; chaîne lourde gamma4 (1-444) [Homo sapiens VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1- 117) -IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfure avec la chaîne légère kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') - IGKC*01, Km3 (108'-214')]; dimère (223-223":226-226")- bisdisulfure timolumab inmunoglobulina G4-kappa, anti-[Homo sapiens AOC3 (amina oxidasa con cobre 3 (EC 1.4.3.21), proteína de adhesión vascular 1, VAP1, VAP-1)],Homo sapiens anticuerpomonoclonal ; Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 538 cadena pesada gamma4 (1-444) [Homo sapiens VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1- 117) -IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfuro con la cadena ligera kappa (1’-214’) [Homo sapiens (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') - IGKC*01, Km3 (108'-214')]; dímero (223-223":226-226")- bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSLRL SCAASGFTFF SYAMHWVRQT PGKGLEWVAV 50 IWFDGSNENY VDSVKGRFTI SRDNSKNTLY LQMNTLRAED TAVYYCARDA 100 WSYFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200 NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FAGGPSVFLF PPKPKDTLMI 250 SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300 SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350 SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400 FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444 Light chain / Chaîne légère / Cadena ligera VIQLTQSPSS LSASVGDRVT ITCRASQGIS RALAWYQQKP GKGPKLLIYD 50 ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEC 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 144-200 258-318 364-422 22''-96'' 144''-200'' 258''-318'' 364''-422'' Intra-L (C23-C104) 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L (CH1 10-CL 126) 131-214' 131''-214''' Inter-H-H (h 8, h 11) 223-223'' 226-226'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 294, 294'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados vadadustatum vadadustat [5-(3-chlorophenyl)-3-hydroxypyridine- 2-carboxamido]acetic acid vadadustat acide [5-(3-chlorophényl)-3-hydroxypyridine- 2-carboxamido]acétique vadadustat ácido [5-(3-clorofenil)-3-hidroxipiridina- 2-carboxamido]acético C14H11ClN2O4 vadastuximabum # vadastuximab immunoglobulin G1-kappa, anti-[Homo sapiens CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], chimeric monoclonal antibody; gamma1 heavy chain (1-447) [Mus musculus VH (IGHV1- 85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 539 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'- 214') [Mus musculus V-KAPPA (IGKV14-111*01 - IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide vadastuximab immunoglobuline G1-kappa, anti-[Homo sapiens CD33 (lectine 3 de type Ig-like liant l’acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-447) [Mus musculus VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dimère (226-226'':229- 229'')-bisdisulfure vadastuximab inmunoglobulina G1-kappa, anti-[Homo sapiens CD33 (lectina de tipo inmunoglobulina 3 que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-447) [Mus musculus VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216- 230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [Mus musculus V-KAPPA (IGKV14- 111*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01, Km3 (108'-214')]; dímero (226-226'':229-229'')- bisdisulfuro Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 540 venglustatum venglustat (3S)-1-azabicyclo[2.2.2]octan-3-yl N-{2-[2-(4-fluorophenyl)- 1,3-thiazol-4-yl]propan-2-yl}carbamate venglustat N-{2-[2-(4-fluorophényl)-1,3-thiazol-4-yl]propan- 2-yl}carbamate de (3S)-1-azabicyclo[2.2.2]octan-3-yle venglustat N-{2-[2-(4-fluorofenil)-1,3-tiazol-4-il]propan-2-il}carbamato de (3S)-1-azabiciclo[2.2.2]octan-3-ilo C20H24FN3O2S N H O O N CH3H3C N S F H H verdiperstatum verdiperstat 1-[2-(propan-2-yloxy)ethyl]-2-sulfanylidene-1,2,3,5- tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one verdiperstat 1-[2-(propan-2-yloxy)éthyl]-2-sulfanylidène-1,2,3,5- tétrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one verdiperstat 1-[2-(propan-2-iloxi)etil]-2-sulfanilideno-1,2,3,5-tetrahidro- 4H-pirrolo[3,2-d]pirimidin-4-ona C11H15N3O2S vobarilizumabum # vobarilizumab immunoglobulin scFv VH-VH’, anti-[Homo sapiens IL6R (interleukin 6 receptor, IL-6R, CD126)] and anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)], humanized monoclonal antibody bispecific single chain; scFv (1-245) [humanized VH anti-IL6R (Homo sapiens IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1- 121) -9-mer tetraglycyl-seryl-triglycyl-seryl linker (122-130) -humanized VH’ anti-ALB (Homo sapiens IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)] vobarilizumab immunoglobuline scFv VH-VH’, anti-[Homo sapiens IL6R (récepteur de l'interleukine 6, IL-6R, CD126)] et anti-[Homo sapiens ALB (albumine, sérum-albumine humaine, SAH)], anticorps monoclonal humanisé et bispécifique à chaîne unique; scFv (1-245) [VH humanisé anti-IL6R (Homo sapiens IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1- 121) -9-mer tétraglycyl-séryl-triglycyl-séryl linker (122-130) -VH’ humanisé anti-ALB (Homo sapiens IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)] WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 541 vobarilizumab inmunoglobulina scFv VH-VH’, anti-[Homo sapiens IL6R (receptor de la interleukina 6, IL-6R, CD126)] y anti-[Homo sapiens ALB (albúmina, albúmina sérica humana, ASH)], anticuerpo monoclonal humanizado biespecífico monocatenario; scFv (1-245) [VH humanizado anti-IL6R (Homo sapiens IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1- 121) -9-mer tetraglicil-seril-triglicil-seril vínculo (122-130) - VH’ humanizado anti-ALB (Homo sapiens IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)] xentuzumabum # xentuzumab immunoglobulin G1-lambda1, anti-[Homo sapiens IGF1 (insulin-like growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor 2, somatomedin A)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with lambda1 light chain (1'-216') [humanized V-LAMBDA (Homo sapiens IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'- 110') -IGLC2*01 A43>G (154) (111'-216')]; dimer (226- 226'':229-229'')-bisdisulfide xentuzumab immunoglobuline G1-lambda1, anti-[Homo sapiens IGF1 (facteur de croissance 1 analogue à l’insuline, somatomédine C) et IGF2 (facteur de croissance 2 analogue à l’insuline, somatomédine A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère lambda1 (1'-216') [V-LAMBDA humanisé (Homo sapiens IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'- 110') -IGLC2*01 A43>G (154) (111'-216')]; dimère (226- 226'':229-229'')-bisdisulfure xentuzumab inmunoglobulina G1-lambda1, anti-[Homo sapiens IGF1 (factor de crecimiento 1 análogo a la insulina, somatomedina C) y IGF2 (factor de crecimiento 2 análogo a la insulina, somatomedina A)], anticuerpo monoclonal humanizado; Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 542 cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfuro con la cadena ligera lambda1 (1'-216') [V-LAMBDA humanizado (Homo sapiens IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'- 110') -IGLC2*01 A43>G (154) (111'-216')]; dímero (226- 226'':229-229'')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLELVSS 50 ITSYGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARNM 100 YTHFDSWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350 LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447 Light chain / Chaîne légère / Cadena ligera DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG SNSVSWYQQL PGTAPKLLIY 50 DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYYCQ SRDTYGYYWV 100 FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150 AWKGDSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200 HEGSTVEKTV APTECS 216 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22''-96'' 144''-200'' 261''-321'' 367''-425'' Intra-L (C23-C104) 22'-89' 138'-197' 22'''-89''' 138'''-197''' Inter-H-L (h 5-CL 126) 220-215' 220''-215''' Inter-H-H (h 11, h 14) 226-226' 229-229'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 297, 297'' Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados zoliflodacinum zoliflodacin (2'R,4'S,4'aS)-11'-fluoro-2',4'-dimethyl-8'-[(4S)-4-methyl- 2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'a-tetrahydro- 6'H-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3- a][1,2]oxaz-olo[4,5-g]quinoline]-2,4,6-trione zoliflodacine (2'R,4'S,4'aS)-11'-fluoro-2',4'-diméthyl-8'-[(4S)-4-méthyl- 2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'a-tétrahydro- 6'H-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3- a][1,2]oxaz-olo[4,5-g]quinoline]-2,4,6-trione zoliflodacina (2'R,4'S,4'aS)-11'-fluoro-2',4'-dimetil-8'-[(4S)-4-metil-2-oxo- 1,3-oxazolidin-3-il]-1',2',4',4'a-tetrahidro-6'H-spiro[1,3- diazinano-5,5'-[1,4]oxazino[4,3-a][1,2]oxaz-olo[4,5- g]quinolina]-2,4,6-triona C22H22FN5O7 WHO Drug Information, Vol. 30, No. 3, 2016 Recommended INN: List 76 543 AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES Recommended International Nonproprietary Names (Rec. INN): List 59 Dénominations communes internationales recommandées (DCI Rec.): Liste 59 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59 (WHO Drug Information, Vol. 22, No. 1, 2008)   p. 58 lonaprisanum lonaprisan replace the chemical name by the following one lonaprisan remplacer le nom chimique par le suivant lonaprisán sustitúyase el nombre químico por el siguiente 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor- 17α-pregna-4,9-dien-3-one 11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor- 17α-prégna-4,9-dién-3-one 11β-(4-acetylfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor- 17α-pregna-4,9-dien-3-ona Recommended International Nonproprietary Names (Rec. INN): List 67 Dénominations communes internationales recommandées (DCI Rec.): Liste 67 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67 (WHO Drug Information, Vol. 26, No. 1, 2012)   p. 58 daclatasvirum daclatasvir replace the chemical name by the following one daclatasvir remplacer le nom chimique par le suivant daclatasvir sustitúyase el nombre químico por el siguiente dimethyl N,N'-([1,1'-biphenyl]-4,4'-diylbis{1H-imidazole-5,2-diyl-[(2S)- pyrrolidine-2,1-diyl][(2S)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate N,N'-([1,1'-biphényl]-4,4'-diylbis{1H-imidazole-5,2-diyl-[(2S)- pyrrolidine-2,1-diyl][(2S)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle N,N'-([1,1'-bifenil]-4,4'-diilbis{1H-imidazol-5,2-diil-[(2S)-pirrolidina- 2,1-diil][(2S)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo Recommended International Nonproprietary Names (Rec. INN): List 71 Recommended INN: List 76 WHO Drug Information, Vol. 30, No. 3, 2016 544 Dénominations communes internationales recommandées (DCI Rec.): Liste 71 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71 (WHO Drug Information, Vol. 28, No. 1, 2014)   p. 90 idarucizumabum - 91 idarucizumab replace the description by the following one idarucizumab remplacer la description par la suivante idarucizumab sustitúyase la descripción por la siguiente immunoglobulin Fab G1-kappa, anti-[dabigatran], humanized monoclonal antibody; VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) - Homo sapiens IGHG1*01 (CH1 (123-220), hinge 1-5 (221-225)) (123- 225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')] immunoglobuline Fab G1-kappa, anti-[dabigatran], anticorps monoclonal humanisé; chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé(Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16](1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), charnière 1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'- 219')] inmunoglobulina Fab G1-kappa, anti-[dabigatrán], anticuerpo monoclonal humanizado; cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado (Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), bisagra 1-5 (221- 225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'- 219') [V-KAPPA humanizado (Homo sapiens IGKV2-30*01 (88.00%)- IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')] Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.